Is Selling Stock Like Marrone Bio Innovations Inc (MBII) After This Double Bottom Winning Strategy?

September 12, 2017 - By Maria Brooks

Investors sentiment decreased to 1 in Q4 2016. Its down 0.29, from 1.29 in 2016Q3. It fall, as 3 investors sold Marrone Bio Innovations Inc shares while 3 reduced holdings. 3 funds opened positions while 3 raised stakes. 9.11 million shares or 2.31% less from 9.33 million shares in 2016Q3 were reported.
Northern owns 22,275 shares for 0% of their portfolio. Geode Mgmt Ltd Co has invested 0% in Marrone Bio Innovations Inc (NASDAQ:MBII). Waddell & Reed Incorporated has invested 0.02% in Marrone Bio Innovations Inc (NASDAQ:MBII). Moreover, Wells Fargo And Company Mn has 0% invested in Marrone Bio Innovations Inc (NASDAQ:MBII). Pennsylvania-based Vanguard Group Incorporated has invested 0% in Marrone Bio Innovations Inc (NASDAQ:MBII). Blackrock Fund has invested 0% of its portfolio in Marrone Bio Innovations Inc (NASDAQ:MBII). Ogorek Anthony Joseph Adv invested 0% of its portfolio in Marrone Bio Innovations Inc (NASDAQ:MBII). Fin Architects Incorporated holds 0% or 3,485 shares. 2,000 are owned by Creative Planning. 80,500 are held by Spark Investment Management Limited Com. Raymond James Fincl Ser Advsrs Inc has 24,022 shares. Hanson Mcclain reported 10,000 shares or 0% of all its holdings. The North Carolina-based State Bank Of America De has invested 0% in Marrone Bio Innovations Inc (NASDAQ:MBII). Primecap Mgmt Commerce Ca invested in 0.01% or 2.84M shares. Morgan Stanley reported 480 shares or 0% of all its holdings.

The chart of Marrone Bio Innovations Inc (MBII) shows a double bottom with $1.13 target or 3.00 % below today’s $1.16 share price. The 9 months chart pattern indicates high risk for the $36.37M company. It was reported on Sep, 12 by Finviz.com. If the $1.13 price target is reached, the company will be worth $1.09 million less. Double bottoms are rare but powerful chart patterns.

It is 0.00% or $0 reaching $1.16 per share. It is down 94.03% since September 12, 2016 and is uptrending. It has outperformed by 77.33% the S&P500.

Marrone Bio Innovations Inc (NASDAQ:MBII) Ratings Coverage

Among 3 analysts covering Marrone Bio Innovations (NASDAQ:MBII), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Marrone Bio Innovations had 5 analyst reports since August 11, 2015 according to SRatingsIntel. The rating was downgraded by Zacks to “Buy” on Tuesday, August 11. H.C. Wainwright maintained Marrone Bio Innovations Inc (NASDAQ:MBII) rating on Tuesday, August 15. H.C. Wainwright has “Buy” rating and $3.5000 target. The stock has “Hold” rating by Piper Jaffray on Friday, July 21. Rodman & Renshaw initiated Marrone Bio Innovations Inc (NASDAQ:MBII) on Wednesday, March 16 with “Buy” rating. Piper Jaffray maintained it with “Hold” rating and $2.0 target in Monday, August 14 report.

More notable recent Marrone Bio Innovations Inc (NASDAQ:MBII) news were published by: Nasdaq.com which released: “Marrone Bio Innovations, Inc. Reports Second Quarter 2017 Financial Results” on August 14, 2017, also Seekingalpha.com with their article: “Short Squeeze Coming In Marrone Bio Innovations?” published on August 28, 2017, Globenewswire.com published: “AgShift Launches Pilot Project with Marrone Bio Innovations to More …” on September 06, 2017. More interesting news about Marrone Bio Innovations Inc (NASDAQ:MBII) were released by: Globenewswire.com and their article: “Marrone Bio Innovations, Inc. Products Show Impressive Results in …” published on July 10, 2017 as well as Seekingalpha.com‘s news article titled: “Marrone Bio Innovations’ (MBII) CEO Pam Marrone on Q1 2017 Results – Earnings …” with publication date: May 12, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.